Theragent and Pluristyx Enter Partnership to Streamline and Advance iPSC-derived Therapy Development
Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell- and tissue-based therapies, has announced a partnership with Pluristyx, Inc., an early stage, privately held biotechnology company specializing in induced Pluripotent Stem Cell (iPSC) products. Combined, this partnership will allow the companies to provide a seamless, end-to-end pathway to therapeutics developers from iPSC derivation to […]
Read More
Theragent Expands Leadership Team with Weifeng “Frank” Zhang as Senior Vice President of Operations
Theragent is proud to welcome Weifeng “Frank” Zhang as Senior Vice President of Operations. Mr. Zhang, joining the team in March of 2024, brings over 25 years of biotech industry experience to the table. Mr. Zhang joins Theragent from his most recent position as Vice President of Manufacturing at Tanvex Biopharma. Prior to working at Tanvex, he served as Vice President […]
Read More
CellVax Therapeutics Announces FDA Clearance of IND Application for FK-PC101, a Novel Personalized Cancer Immunotherapy
FK-PC101 is CellVax’s novel personalized cancer immunotherapy intended to treat prostate cancer patients who have a high risk of recurrence after prostatectomy. It consists of patient’s own tumor cells which are collected during surgery, then modified in the laboratory. The modified cells express Major Histocompatibility Complex (MHC) Class II on their surface, which are then […]
Read MoreCellVax Submits IND Application for Individualized Cell-based Immunotherapy FK-PC101 with Support of Theragent
Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, announced that their sponsor client, CellVax Therapeutics Inc., has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for FK-PC101. CellVax and Theragent partnered in November of 2022, with CellVax seeking clearance to proceed with their Phase II adaptive design […]
Read More
Theragent Welcomes Seasoned Cell Therapy Professional Brian Newsom as New Vice President of Business Development
Theragent, a comprehensive cell & gene therapy CDMO focused on advancing next-generation cancer and rare disease treatments, announced that Brian Newsom will be joining the team as their new Vice President of Business Development effective October 16th, 2023. Mr. Newsom will join Theragent from his latest role as Senior Director of Business Development at KBI […]
Read More
Theragent Embraces Pharma 4.0 with AI Software Provider, Insight68
Theragent, a cell therapy CDMO focused on advancing next-generation cancer and rare disease treatments, has signed a multi-year exclusive contract with Insight68, an AI-driven software provider that aims to digitalize and streamline the cell therapy manufacturing process. This partnership reinforces Theragent’s commitment to 100% digital batch record compliance and elevates the company’s reputation as a […]
Read More
Theragent Secures Novel Stem Cell Bank Production Contract with Accelerated Biosciences
Theragent has announced an agreement with Accelerated Biosciences, a regenerative medicine innovator, to produce the cGMP-grade master cell bank (MCB) for Accelerated Biosciences’ novel human Trophoblast Stem Cells (hTSCs). Accelerated Biosciences’ hTSCs are pluripotent and immune-privileged stem cells that are derived from an ethical source and can be differentiated into a number of cell therapies. […]
Read More
CellVax Selects Theragent as Manufacturing Partner for Phase 2 Clinical Trial for Prostate Cancer Immunotherapy
Theragent, a cell therapy Contract Development and Manufacturing Organization (CDMO) focused on advancing next-generation cancer and rare disease treatments, has announced that they have been selected by CellVax Therapeutics to provide manufacturing and testing services for CellVax’s novel cancer immunotherapy candidate FK-PC101 entering Phase 2 clinical trials. FK-PC101 is a cell-based autologous cancer vaccine for […]
Read More